Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility.

D'Alessandro R, Refolo MG, Iacovazzi PA, Pesole PL, Messa C, Carr BI.

Cancers (Basel). 2019 Jun 7;11(6). pii: E787. doi: 10.3390/cancers11060787.

2.
3.

Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics.

Suner A, Carr BI, Akkiz H, Uskudar O, Kuran S, Tokat Y, Tokmak S, Ballı T, Ulku A, AkCam T, Delik A, Arslan B, Doran F, YalCın K, Ekinci N, Yilmaz S, Ozakyol A, Yücesoy M, BahCeci HI, Polat KY, Şimsek H, Ormeci N, Sonsuz A, Demir M, KılıC M, Uygun A, Demir A, Altıntas E, Karakulah G, Temel T, Bektas A.

J Transl Sci. 2019 Jun;5(3). doi: 10.15761/JTS.1000260. Epub 2018 Jun 22.

4.

Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma.

Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N.

Can J Gastroenterol Hepatol. 2018 Oct 22;2018:7568742. doi: 10.1155/2018/7568742. eCollection 2018. Review.

5.

C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma.

Suner A, Carr BI, Akkiz H, Karakülah G, Üsküdar O, Yalçın K, Kuran S, Tokat Y, Yilmaz S, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Altıntaş E, Temel T, Bektaş A.

Oncology. 2019;96(1):25-32. doi: 10.1159/000492473. Epub 2018 Oct 18.

PMID:
30336489
6.

Macroscopic Portal Vein Thrombosis in HCC Patients.

Akkiz H, Carr BI, Kuran S, Karaoğullarından Ü, Üsküdar O, Tokmak S, Arslan B, Doran F, Balli HT, Ülkü A, Akçam TA, Bahçeci Hİ, Polat KY, Örmeci N, Şimşek H, Sonsuz A, Demir A, Altıntaş E, Demir M, Yalçın K, Ekinci N, Harmancı Özakyol A, Yücesoy M, Uygun A, Guerra V, Delik A, Tokat Y, Yilmaz S, Bektaş A, Kılıç M.

Can J Gastroenterol Hepatol. 2018 Jun 13;2018:3120185. doi: 10.1155/2018/3120185. eCollection 2018.

7.

C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Carr BI, Akkiz H, Guerra V, Üsküdar O, Kuran S, Karaoğullarından Ü, Tokmak S, Ballı T, Ülkü A, Akçam T, Delik A, Arslan B, Doran F, Yalçın K, Altntaş E, Özakyol A, Yücesoy M, Bahçeci Hİ, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Yilmaz S, Tokat Y.

Clin Pract (Lond). 2018;15(Spec Issue):625-634. doi: 10.4172/clinical-practice.1000409.

8.

Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients.

Carr BI, Giannelli G, Guerra V, Giannini EG, Farinati F, Rapaccini GL, Marco MD, Zoli M, Caturelli E, Masotto A, Virdone R, Sacco R, Trevisani F.

Int J Biol Markers. 2018 Nov;33(4):423-431. doi: 10.1177/1724600818776838. Epub 2018 Jun 6.

PMID:
29874983
9.

Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization.

Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O.

World J Gastroenterol. 2018 Apr 21;24(15):1641-1649. doi: 10.3748/wjg.v24.i15.1641.

10.

HCC with low- and normal-serum alpha-fetoprotein levels.

Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Yilmaz S, Tokat Y.

Clin Pract (Lond). 2018;15(1):453-464. doi: 10.4172/clinical-practice.1000393.

11.

Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.

D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.

Cell Oncol (Dordr). 2018 Jun;41(3):283-296. doi: 10.1007/s13402-018-0370-z. Epub 2018 Feb 22.

PMID:
29470830
12.

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.

Refolo MG, D'Alessandro R, Lippolis C, Carella N, Cavallini A, Messa C, Carr BI.

Oncotarget. 2017 Sep 30;8(61):103465-103476. doi: 10.18632/oncotarget.21403. eCollection 2017 Nov 28.

13.

Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.

Akkiz H, Carr BI, Yalçın K K, Guerra V, Kuran S, Altıntaş E, Üsküdar O, Karaoğullarından Ü, Özakyol A, Tokmak S, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Yalçın Polat K, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Ballı T, Demir A, Arslan B, Doran F.

Oncology. 2018;94(2):116-124. doi: 10.1159/000484564. Epub 2017 Dec 6.

14.

Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients.

Carr BI, Guerra V.

Int J Biol Markers. 2017 Oct 31;32(4):e391-e396. doi: 10.5301/ijbm.5000300.

PMID:
28862714
15.

Validation of a Liver Index and Its Significance for HCC Aggressiveness.

Carr BI, Guerra V.

J Gastrointest Cancer. 2017 Jun 20. doi: 10.1007/s12029-017-9971-4. [Epub ahead of print]

PMID:
28631027
16.

A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F.

J Integr Oncol. 2016 Oct;5(4). pii: 178. doi: 10.4172/2329-6771.1000178. Epub 2016 Sep 5.

17.

Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma.

Bağırsakçı E, Şahin E, Atabey N, Erdal E, Guerra V, Carr BI.

Oncology. 2017;93(2):136-142. doi: 10.1159/000471807. Epub 2017 May 10.

PMID:
28486226
18.

New Developments in Orthotopic Liver Transplant for Hepatocellular Carcinoma.

Marino IR, Carr BI.

Exp Clin Transplant. 2017 Mar;15(Suppl 2):1-6. Review.

19.

Liver Transplantation for a Patient with Hepatocellular Carcinoma with Vascular Invasion and Exceeding Milan Criteria-Happy End Despite it all.

Rozen R, Menachem Y, Carr BI, Shibolet O.

J Gastrointest Cancer. 2018 Jun;49(2):214-217. doi: 10.1007/s12029-016-9890-9. No abstract available.

PMID:
27834046
20.

The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.

Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI.

J Hepatol. 2017 Feb;66(2):338-346. doi: 10.1016/j.jhep.2016.09.008. Epub 2016 Sep 24.

21.

A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm.

Mazzocca A, Ferraro G, Misciagna G, Carr BI.

Med Hypotheses. 2016 Aug;93:132-7. doi: 10.1016/j.mehy.2016.05.027. Epub 2016 May 24.

PMID:
27372872
22.

A Hepatocellular Carcinoma Aggressiveness Index and Its Relationship to Liver Enzyme Levels.

Carr BI, Guerra V.

Oncology. 2016;90(4):215-20. doi: 10.1159/000444394. Epub 2016 Mar 15.

PMID:
26974336
23.

Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.

Carr BI, Guerra V.

Dig Dis Sci. 2016 Apr;61(4):1210. doi: 10.1007/s10620-016-4088-3. No abstract available.

PMID:
26921077
24.

Hepatocellular Carcinoma Extrahepatic Metastasis in Relation to Tumor Size and Alkaline Phosphatase Levels.

Carr BI, Guerra V.

Oncology. 2016;90(3):136-42. doi: 10.1159/000443480. Epub 2016 Feb 12.

PMID:
26866819
25.

Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.

Carr BI, Guerra V.

Dig Dis Sci. 2016 Mar;61(3):937-47. doi: 10.1007/s10620-015-3922-3. Epub 2015 Nov 17. Erratum in: Dig Dis Sci. 2016 Apr;61(4):1210.

PMID:
26576554
26.

Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.

D'Alessandro R, Messa C, Refolo MG, Carr BI.

Expert Opin Pharmacother. 2015;16(18):2773-80. doi: 10.1517/14656566.2015.1101065. Epub 2015 Oct 19. Review.

PMID:
26479083
27.

Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.

Lippolis C, Refolo MG, D'Alessandro R, Carella N, Messa C, Cavallini A, Carr BI.

J Exp Clin Cancer Res. 2015 Sep 2;34:90. doi: 10.1186/s13046-015-0210-1.

29.

Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.

Facciorusso A, Del Prete V, Crucinio N, Muscatiello N, Carr BI, Di Leo A, Barone M.

J Gastroenterol Hepatol. 2015 Nov;30(11):1643-50. doi: 10.1111/jgh.12988.

PMID:
25974743
30.

MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.

Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):993-1003. doi: 10.1586/17474124.2015.1040763. Epub 2015 Apr 27. Review.

PMID:
25915713
31.

Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.

D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1237-1245. doi: 10.1007/s00280-015-2751-6. Epub 2015 Apr 24.

32.

Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis.

Pančoška P, Skála L, Nešetřil J, Carr BI.

Semin Oncol. 2015 Apr;42(2):339-46. doi: 10.1053/j.seminoncol.2014.12.025. Epub 2015 Jan 5.

33.

A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinoma.

Carr BI, Guerra V, Steel JL, Lu SN.

Semin Oncol. 2015 Apr;42(2):309-15. doi: 10.1053/j.seminoncol.2014.12.019. Epub 2015 Jan 28.

PMID:
25843735
34.

Viruses and cancer: introduction.

Carr BI.

Semin Oncol. 2015 Apr;42(2):189-90. doi: 10.1053/j.seminoncol.2014.12.031. Epub 2014 Dec 31. No abstract available.

PMID:
25843725
35.

Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation.

Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A, Carr BI, Barone M.

Dig Liver Dis. 2014 Nov;46(11):1014-9. doi: 10.1016/j.dld.2014.07.012. Epub 2014 Jul 29.

PMID:
25085684
36.

Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Carr BI, Lin CY, Lu SN.

Semin Oncol. 2014 Jun;41(3):415-21. doi: 10.1053/j.seminoncol.2014.04.001. Epub 2014 Apr 23.

37.

Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Semin Oncol. 2014 Jun;41(3):406-414. doi: 10.1053/j.seminoncol.2014.04.002. Epub 2014 Apr 24.

38.

Guest editorial: Platelets and cancer.

Carr BI.

Semin Oncol. 2014 Jun;41(3):300-1. doi: 10.1053/j.seminoncol.2014.04.011. Epub 2014 Apr 24. No abstract available. Erratum in: Semin Oncol. 2014 Oct;41(5):e49.

PMID:
25023345
39.

Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates.

Refolo MG, D'Alessandro R, Lippolis C, Messa C, Carella N, Cavallini A, Carr BI.

Anticancer Agents Med Chem. 2014;14(8):1154-60.

PMID:
24934165
40.

Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.

D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, Carella N, Messa C, Cavallini A, Carr BI.

BMC Cancer. 2014 May 21;14:351. doi: 10.1186/1471-2407-14-351.

41.

Low alpha-fetoprotein HCC and the role of GGTP.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F.

Int J Biol Markers. 2014 Dec 9;29(4):e395-402. doi: 10.5301/jbm.5000092.

PMID:
24832180
42.

Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Semin Oncol. 2014 Apr;41(2):252-8. doi: 10.1053/j.seminoncol.2014.03.006. Epub 2014 Mar 6.

43.

Macro- and micro-environmental factors in clinical hepatocellular cancer.

Pancoska P, Carr BI.

Semin Oncol. 2014 Apr;41(2):185-94. doi: 10.1053/j.seminoncol.2014.03.001. Epub 2014 Mar 7.

44.

A systematic review of randomized controlled trials testing the efficacy of psychosocial interventions for gastrointestinal cancers.

Steel JL, Bress K, Popichak L, Evans JS, Savkova A, Biala M, Ordos J, Carr BI.

J Gastrointest Cancer. 2014 Jun;45(2):181-9. doi: 10.1007/s12029-014-9605-z. Review.

PMID:
24733568
45.

Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation.

Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, Carr BI, Barone M.

J Gastroenterol Hepatol. 2014 Nov;29(11):1905-10. doi: 10.1111/jgh.12618.

PMID:
24731153
46.

Significance of platelet and AFP levels and liver function parameters for HCC size and survival.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer Group.

Int J Biol Markers. 2014 Sep 30;29(3):e215-23. doi: 10.5301/jbm.5000064.

PMID:
24526315
47.

Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.

Carr BI, Cavallini A, D'Alessandro R, Refolo MG, Lippolis C, Mazzocca A, Messa C.

BMC Cancer. 2014 Jan 27;14:43. doi: 10.1186/1471-2407-14-43.

48.

Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase.

Carr BI, Guerra V.

Oncology. 2013;85(3):153-9. doi: 10.1159/000354416. Epub 2013 Aug 29.

49.

Reversibility of regorafenib effects in hepatocellular carcinoma cells.

D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI.

Cancer Chemother Pharmacol. 2013 Oct;72(4):869-77.

50.

Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.

Pancoska P, Lu SN, Carr BI.

J Gastrointest Dig Syst. 2013 Mar 2;Suppl 12. pii: 001.

Supplemental Content

Support Center